New combo aims to boost transplant success in tough lymphoma

NCT ID NCT07451652

Recruiting now Disease control Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Source: ClinicalTrials.gov ↗

First seen Mar 06, 2026 · Last updated May 08, 2026 · Updated 9 times

Summary

This study tests a lower dose of the drug epcoritamab combined with chemotherapy (gemcitabine and oxaliplatin) in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors enough to allow for a stem cell transplant. About 10 participants who are eligible for transplant will receive the treatment, and researchers will monitor how well it works and any side effects like cytokine release syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Universitario "Dr. José Eleuterio González"
RECRUITING

Monterrey, Nuevo León, 64640, Mexico

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA